{"id":249903,"date":"2023-05-29T00:00:00","date_gmt":"2023-05-29T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0111-biopharma-axial-spondyloarthritis-epidemiology-asia\/"},"modified":"2026-03-31T10:33:14","modified_gmt":"2026-03-31T10:33:14","slug":"epidim0111-biopharma-axial-spondyloarthritis-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0111-biopharma-axial-spondyloarthritis-epidemiology-asia-pacific\/","title":{"rendered":"Axial Spondyloarthritis &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of axial spondyloarthritis (<abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of ankylosing spondylitis (<abbr title=\"ankylosing spondylitis\">AS<\/abbr>).<\/li>\n<li>Total prevalent cases of nonradiographic axial spondyloarthritis (<abbr title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr>).<\/li>\n<li>Total prevalent cases of <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> by <abbr title=\"human leukocyte antigen\">HLA<\/abbr>-B27 status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"ankylosing spondylitis\">AS<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr> by drug-treatment status.<\/li>\n<li>Total prevalent cases of <abbr title=\"axial spondyloarthritis\">AxSpA<\/abbr> by diagnosis status.<\/li>\n<li>Total prevalent cases of <abbr title=\"ankylosing spondylitis\">AS<\/abbr> by diagnosis status.<\/li>\n<li>Total prevalent cases of <abbr title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr> by diagnosis status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249903","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-therapy-areas-rheumatology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249903\/revisions"}],"predecessor-version":[{"id":281543,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249903\/revisions\/281543"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}